Cargando…

Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations

OBJECTIVES: The objective was to seek evidence on the prevalence and consequences of heterozygous CYP21A2 mutations in girls, adolescent, and adult females with clinical manifestation of androgen excess. PATIENTS AND METHODS: The study included 64 girls diagnosed with premature adrenarche (PA) in ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Neocleous, Vassos, Shammas, Christos, Phedonos, Alexia AP, Phylactou, Leonidas A, Skordis, Nicos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266872/
https://www.ncbi.nlm.nih.gov/pubmed/25538881
http://dx.doi.org/10.4103/2230-8210.145077
_version_ 1782349069519159296
author Neocleous, Vassos
Shammas, Christos
Phedonos, Alexia AP
Phylactou, Leonidas A
Skordis, Nicos
author_facet Neocleous, Vassos
Shammas, Christos
Phedonos, Alexia AP
Phylactou, Leonidas A
Skordis, Nicos
author_sort Neocleous, Vassos
collection PubMed
description OBJECTIVES: The objective was to seek evidence on the prevalence and consequences of heterozygous CYP21A2 mutations in girls, adolescent, and adult females with clinical manifestation of androgen excess. PATIENTS AND METHODS: The study included 64 girls diagnosed with premature adrenarche (PA) in childhood and 141 females with clinical hyperandrogenemia manifested in adolescence or adulthood. Direct DNA sequencing and multiplex ligation-dependent probe amplification analysis were used to identify mutations in the CYP21A2 gene. RESULTS: (1) Thirty-four patients were diagnosed with nonclassical-congenital adrenal hyperplasia (NC-CAH) based on the 17-hydroxyprogesterone (17-OHP) levels and the presence of two mutations in CYP21A2 and therefore were excluded from the study, 66 were found to be heterozygotes and finally 105 had no identifiable mutations. The most frequent mutations among the carriers were the mild p.Val281 Leu and p.Qln318stop. Higher levels of mean stimulated 17-OHP were found in the carriers of the p.Val281 Leu. (2) A notable increased allelic frequency for the known p.Asn493 Ser polymorphism was observed in the pool of females with hyperandrogenemia in whom no mutation was identified. (3) In girls, who presented early with PA, 26.6% were diagnosed with NC-CAH and carried two mutations, 28.7% were identified as heterozygotes 43.7% had no identifiable genetic defect in the translated region of the CYP21A2 gene. On the contrary, in the group of 141 females with late onset hyperandrogenemia, the presence of 2 mutations was detected in 12%, 1 mutation in 33.4% and no mutation in 54.6%. CONCLUSIONS: The carrier status for 21-OHD, may be an important factor in the variable phenotype of hyperandrogenism and may be a contributing factor for the early manifestation of the disease.
format Online
Article
Text
id pubmed-4266872
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-42668722014-12-23 Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations Neocleous, Vassos Shammas, Christos Phedonos, Alexia AP Phylactou, Leonidas A Skordis, Nicos Indian J Endocrinol Metab Original Article OBJECTIVES: The objective was to seek evidence on the prevalence and consequences of heterozygous CYP21A2 mutations in girls, adolescent, and adult females with clinical manifestation of androgen excess. PATIENTS AND METHODS: The study included 64 girls diagnosed with premature adrenarche (PA) in childhood and 141 females with clinical hyperandrogenemia manifested in adolescence or adulthood. Direct DNA sequencing and multiplex ligation-dependent probe amplification analysis were used to identify mutations in the CYP21A2 gene. RESULTS: (1) Thirty-four patients were diagnosed with nonclassical-congenital adrenal hyperplasia (NC-CAH) based on the 17-hydroxyprogesterone (17-OHP) levels and the presence of two mutations in CYP21A2 and therefore were excluded from the study, 66 were found to be heterozygotes and finally 105 had no identifiable mutations. The most frequent mutations among the carriers were the mild p.Val281 Leu and p.Qln318stop. Higher levels of mean stimulated 17-OHP were found in the carriers of the p.Val281 Leu. (2) A notable increased allelic frequency for the known p.Asn493 Ser polymorphism was observed in the pool of females with hyperandrogenemia in whom no mutation was identified. (3) In girls, who presented early with PA, 26.6% were diagnosed with NC-CAH and carried two mutations, 28.7% were identified as heterozygotes 43.7% had no identifiable genetic defect in the translated region of the CYP21A2 gene. On the contrary, in the group of 141 females with late onset hyperandrogenemia, the presence of 2 mutations was detected in 12%, 1 mutation in 33.4% and no mutation in 54.6%. CONCLUSIONS: The carrier status for 21-OHD, may be an important factor in the variable phenotype of hyperandrogenism and may be a contributing factor for the early manifestation of the disease. Medknow Publications & Media Pvt Ltd 2014-11 /pmc/articles/PMC4266872/ /pubmed/25538881 http://dx.doi.org/10.4103/2230-8210.145077 Text en Copyright: © Indian Journal of Endocrinology and Metabolism http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Neocleous, Vassos
Shammas, Christos
Phedonos, Alexia AP
Phylactou, Leonidas A
Skordis, Nicos
Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations
title Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations
title_full Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations
title_fullStr Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations
title_full_unstemmed Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations
title_short Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations
title_sort phenotypic variability of hyperandrogenemia in females heterozygous for cyp21a2 mutations
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266872/
https://www.ncbi.nlm.nih.gov/pubmed/25538881
http://dx.doi.org/10.4103/2230-8210.145077
work_keys_str_mv AT neocleousvassos phenotypicvariabilityofhyperandrogenemiainfemalesheterozygousforcyp21a2mutations
AT shammaschristos phenotypicvariabilityofhyperandrogenemiainfemalesheterozygousforcyp21a2mutations
AT phedonosalexiaap phenotypicvariabilityofhyperandrogenemiainfemalesheterozygousforcyp21a2mutations
AT phylactouleonidasa phenotypicvariabilityofhyperandrogenemiainfemalesheterozygousforcyp21a2mutations
AT skordisnicos phenotypicvariabilityofhyperandrogenemiainfemalesheterozygousforcyp21a2mutations